Affiliated Hospital

Guiyang, China

Affiliated Hospital

Guiyang, China

Time filter

Source Type

Yuan Y.,Affiliated Hospital
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology | Year: 2016

OBJECTIVE: To establish a rat model of nonalcoholic fatty liver disease (NAFLD) using high-fat diet, and to dynamically observe the influence of the changes in gut microbiota on the development and progression of NAFLD in rats during and after modeling.METHODS: Sprague-Dawley rats were given high-fat diet to establish the model of NAFLD, and these rats were randomly divided into high-fat group, antibiotic pretreatment group, antibiotic treatment group, restricted diet group, and control group. The rats were sacrificed in different feeding periods, and 16sRNA fluorescent quantitative PCR was used to analyze the changes in ileocecal microbiota in rats. The liver pathological scores were determined, and enzymatic colorimetry was used to measure blood lipid level in serum and liver homogenate. The sample mean t-test was used for comparison between groups.RESULTS: Compared with the high-fat group, the restricted diet group showed the most significant improvements in quality of life and biochemical parameters. In the restricted diet group, the number of probiotics (Bifidobacterium and Lactobacillus) at the end of the ileum gradually increased and tended to increase over the time of intervention, and the most significant difference between this group and the high-fat group occurred at the 10th week (Bifidobacterium: 0.91±0.23 vs 0.28±0.12, P < 0.05; Lactobacillus: 0.78±0.04 vs 0.21±0.03, P < 0.05), while the number of enterococci decreased. There were no significant differences in enteric bacilli between groups (all P > 0.05). At the 10th week, the liver pathological scores in the control group, antibiotic treatment group, and restricted diet group were 1.13±1.74, 4.86±0.86, and 2.94±1.91, respectively, significantly lower than 7.09±2.03 in the high fat group (all P < 0.05).CONCLUSION: Diet structure change and antibiotic intervention can adjust gut microecology, alleviate the lesions of NAFLD, and thus provide new strategies for the prevention and treatment of NAFLD from the perspective of microecology.


Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases A future where faecal transplants in China will cure conditions like autism, IBD, arthritis, Parkinson's disease and even MS was presented by global Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) at the opening of the China Microbiota Transplantation Conference in Nanjing, in his keynote presentation on non Clostridium difficile conditions (April 12-14, 2017). Professor Borody, the founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney, Australia said many diseases have a unique microbiome profile which can be progressively changed to a normal profile with FMT treatment (www.cdd.com.au). The conference, hosted by the Chinese Medical Doctor Association, attracted more than 700 attendees with 50 oral presentations from China, Australia, USA and Europe. FMT has its origins in China with earliest treatments dating back to the 4th century. Prof. Borody is at the forefront of FMT research being first to report successful treatment of IBD in 1988. He invented, among other therapies, the freeze-dried oral FMT capsule system. He is also globally recognized as the first physician to successfully formulate the highly effective Triple Therapy that become the gold standard for treating Helicobacter pylori infection, which can lead to peptic ulcers and stomach cancer, so common in China. Prof. Borody in his presentation also shared findings from recent ground-breaking clinical trials in IBD and autism that he personally designed and was involved as an example of the need for greater FMT clinical trial investment in serious diseases: -- The FOCUS Study -- the first adequately powered randomized double blind controlled trial for ulcerative colitis -- The Autism Study -- where cognitive improvement change was found after just 5 weeks of treatment At the CDD, Prof. Borody has had success using FMT in a broad range of conditions including IBS, IBD, autism and other neurological and autoimmune diseases. He said more research funding was needed to bring FMT treatment into the mainstream medical world. "We've seen profound remission in three MS patients that are out of wheelchairs," he said. Like the US and Australia China is facing increasing challenges around the management of diseases, many with rising incidence including IBD, Parkinson's disease, MS, and many autoimmune conditions. At the state-of-the-art CDD facility in Sydney Prof. Borody and his team have performed more than 12,000 FMTs. "The healthy human flora or its components, appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonization of the damaged gut microbiome," said Prof. Borody. Prior to the conference Prof. Borody visited the FMT Bank in Nanjing with China's FMT leader Professor Faming Zhang, who was the first to perform FMT in China and has carried out over 1600 treatments to date. Prof. Borody has collaborated closely with Professor Faming Zhang, the Director of Intestinal Diseases Center at the 2nd Affiliated Hospital, Nanjing Medical University. About: What is Faecal Microbiota Transplantation The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria. FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition. The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions. The Centre for Digestive Diseases offers FMT primarily for the treatment of Clostridium difficile and treats selected patients with ulcerative colitis, irritable bowel sydrome, constipation and Crohn's disease. Other conditions are assessed on a case by case basis. About: Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist (www.cdd.com.au) Prof. Thomas Borody is the founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments. Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments. Contact: Susan Fitzpatrick-Napier Digital Mantra Group SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238 Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases A future where faecal transplants in China will cure conditions like autism, IBD, arthritis, Parkinson's disease and even MS was presented by global Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) in his keynote presentation on non Clostridium difficile conditions, to open the international China Microbiota Transplantation Conference in Nanjing (April 12-14, 2017). Professor Borody, the Founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney, Australia said many diseases have a unique microbiome profile which can be progressively changed to a normal profile with FMT treatment. At the state-of-the-art CDD facility, Prof. Borody and his team have performed more than 12,000 FMTs. Prof. Borody is at the forefront of FMT research, being the first to report successful treatment of IBD in 1988. He invented, among other therapies, the freeze-dried oral FMT capsule system. He is also recognized as the first physician to successfully formulate the highly effective Triple Therapy that would become the gold standard for treating Helicobacter pylori infection, which can lead to peptic ulcers and stomach cancer, so common in China. In his keynote presentation, Prof. Borody also shared findings from recent ground-breaking clinical trials in IBD and autism, which he personally designed and remained involved in, as examples of the need for greater FMT clinical trial investment in serious diseases: -- The FOCUS Study - the first adequately powered randomized double blind controlled trial for ulcerative colitis -- The Autism Study - where cognitive improvement change was found after just 5 weeks of treatment He said more research funding was needed to bring FMT treatment into the mainstream medical world. "The healthy human flora or its components, appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonization of the damaged gut microbiome," said Prof. Borody. Prior to the conference Prof. Borody visited the FMT Bank in Nanjing with China's FMT leader Professor Faming Zhang, who was the first to perform FMT in China and has carried out over 1600 treatments to date. Prof. Borody has collaborated closely with Professor Faming Zhang, who is the Director of Intestinal Diseases Center at the 2nd Affiliated Hospital, Nanjing Medical University. Like the US and Australia, China is facing increasing challenges around the management of diseases, many with rising incidence including IBD, Parkinson's disease, MS, and many autoimmune conditions. About: What is Faecal Microbiota Transplantation The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria. FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition. The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions. The Centre for Digestive Diseases offers FMT primarily for the treatment of Clostridium difficile and treats selected patients with ulcerative colitis, irritable bowel sydrome, constipation and Crohn's disease. Other conditions are assessed on a case by case basis. About: Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist (www.cdd.com.au) Prof. Thomas Borody is the founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments. Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments. Contact: Susan Fitzpatrick-Napier Digital Mantra Group SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238


News Article | April 24, 2017
Site: www.businesswire.com

PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the first two installations of EOS systems in China at Nanjing Drum Tower Hospital and Ruijin Hospital. Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, provides service to approximately 80 million residents of Jiangsu Province. The hospital is a reference center in China for adult and pediatric orthopedic and spi


News Article | April 24, 2017
Site: www.businesswire.com

PARIS--(BUSINESS WIRE)--Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the first two installations of EOS systems in China at Nanjing Drum Tower Hospital and Ruijin Hospital. Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, provides service to approximately 80 million residents of Jiangsu Province. The hospital is a reference center in China for adult and pediatric


The International Association of HealthCare Professionals is pleased to welcome Robert Roy Recker, MD, FACE, MACP, Endocrinologist, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. He is a highly trained and qualified endocrinologist with an extensive expertise in all facets of his work. Dr. Robert Roy Recker has been in practice for more than 53 years and is currently serving as a Professor of Medicine and Endocrinologist at Alegent Creighton Clinic in Omaha, Nebraska. Additionally, he is affiliated with Creighton University Medical Center. Dr. Recker graduated with his Medical Degree in 1963 from the Creighton University School of Medicine in Omaha, Nebraska where he is now currently working. Following his graduation, Dr. Recker completed his internship at Wilford Hall USAF Hospital, prior to completing his residency and then fellowship at Creighton University School of Medicine and Affiliated Hospital. Dr. Recker holds board certification by the American Board of Internal Medicine, is nationally renowned as an expert in endocrinology, diabetes and metabolism, and is renowned as one of America’s foremost experts on osteoporosis and postmenopausal osteoporosis. He is the Director of the Osteoporosis Research Center, and Associate Editor of BONE journal. Dr. Recker has had many articles published in this area, and has earned the coveted title of Fellow of the American College of Endocrinology, and Master of the American College of Physicians. Dr. Recker attributes his great success to his research skills as well as his desire to make a difference. When he is not working, Dr. Recker enjoys skiing and sailing. Learn more about Dr. Recker by reading his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


Huang T.,Affiliated Hospital | Chen Z.,Affiliated Hospital | Fang L.,Jinling Hospital of Nanjing
Oncology Reports | Year: 2013

Epithelial-mesenchymal transition (EMT) is considered a critical event in cancer cell invasion and metastasis. Emerging evidence has shown that curcumin may prevent or delay the progression of cancer, an effect that may be partially due to its ability to disrupt EMT, yet this has not yet been demonstrated. In this study, we used lipopolysaccharide (LPS) to trigger EMT in MCF-7 and MDA-MB-231 breast cancer cell lines and showed that curcumin inhibited LPS-induced morphological changes, decreased the expression of LPS-induced markers of EMT such as vimentin, and increased the expression of E-cadherin, resulting in the inhibition of in vitro cell motility and invasiveness. We discovered that these actions were mediated through the inactivation of NF-?B-Snail signaling pathways. Our results indicate that curcumin plays an important role in the inhibition of LPS-induced EMT in breast cancer cells through the downregulation of NF-?B-Snail activity. These data provide a new perspective of the anti-invasive mechanism of curcumin, indicating that the effect is partly due to its ability to attack the EMT process.


Wang Y.,Affiliated Hospital
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] | Year: 2012

To explore the correlation between single nucleotide polymorphisms (SNPs) of interleukin-28B (IL-28B) gene and the susceptibility to primary hepatocellular carcinoma (HCC). A total of 300 histologically confirmed HCC cases (from November 2001 to April 2010) and 310 healthy controls with no history of chronic hepatitis B or hepatocellular carcinoma (2009-2010) were selected from a hospital in Guilin and a hospital in Beijing for this case-control study.139 HCC patients in the case group had complete clinical tracking data. All the subjects were Han Chinese, with no age or gender restrictions.2 ml peripheral blood samples were drawn from each subject with informed consent. SNP of rs12972991, rs4803223, rs8099917 and rs12979860 four loci in IL-28B gene were analyzed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF). The frequencies of C allele at rs12972991, G allele at rs8099917 and G allele at rs4803223 were 6.7% (40/598), 7.9% (47/598) and 10.0% (59/588) respectively in case group; all higher than the corresponding frequencies in control group, separately 2.9% (18/618), 4.1% (25/616) and 3.6% (21/608). The differences were statistically significant (χ2=9.542, 7.858, 20.736, P values all<0.05). The above alleles could increase the risk of HCC, and the OR (95%CI) values were separately 1.67 (1.13-2.46), 1.49 (1.08-2.06) and 2.91 (1.79-4.72). The genotype frequencies of AC+CC at rs12972991, GT+GG at rs8099917, GA+GG at rs4803223 were 13.0% (39/299), 14.7% (44/299) and 19.0% (56/296) respectively in case group; while the frequencies were lower in control group, separately 5.8% (18/309), 8.1% (25/308) and 6.6% (20/304). The differences were statistically significant (χ2=9.319, 6.557, 20.948, P values all<0.05). These genotypes may increase the risk of HCC, and the adjusted OR (95%CI) values were 2.24 (1.31-3.83), 1.81 (1.14-2.88) and 2.90 (1.78-4.70), respectively. The stratified analysis of the clinical data indicated that the frequency of genotype GA+GG at rs4803223 was 50.0% (13/26) in patients of tumor thrombosis in portal vein (TTPV), higher than the frequency of genotype AA (21.1%, 23/109). The difference was statistically significant (χ2=8.965, P=0.003). The results suggested that IL-28B gene polymorphisms was correlated to the susceptibility to HCC in Chinese Han ethnic population. Among them, GA + GG genotype at rs4803223 could increase the risk of TTPV in HCC patients.


Wei L.Q.,Affiliated Hospital
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences | Year: 2011

To investigate the effects of atorvastatin on matrix metalloproteinase-9 (MMP-9) and the tissue inhibitor-1 of matrix metalloproteinase (TIMP-1) levels in bronchoalveolar lavage fluid (BALF) and serum of rats with experimental pulmonary fibrosis. Pulmonary fibrosis was induced by intratracheal administration of bleomycin in 30 female rats, which were further divided into two groups: Group M (without treatment) and Group A (treated with atorvastatin 10 mg/kg); control group (n = 5, Group C) was intratracheally administrated with same volume of saline. Five animals were sacrificed at 2 weeks (M2 and A2), 4 weeks (M4 and A4) and 6 weeks (M6 and A6) after model establishment, respectively. Lung tissue samples were harvested and prepared for HE and Masson's trichrome staining. Concentrations of MMP-9 and TIMP-1 in BALF and serum were measured by ELISA. The severity of inflammation and pulmonary fibrosis was significantly reduced in Group A than that in Group M, especially at week 6. No significant difference was noted in the serum concentrations of MMP-9 and TIMP-1 among the Group M, A and Group C. The BALF concentrations of MMP-9 in Group M2 and M6 were significantly higher than those in Group C (P < 0.01 and 0.05), whereas those in the atorvastatin groups (A2, A4 and A6) were lower than those in M2, M4 and M6. Although the MMP-9 was still higher in Groups A2 and A4 than in the Group C, there was no significant difference in MMP-9 between Group A6 and Group C. TIMP-1 levels in BALF were significantly higher in M4 and M6 than Group C (P < 0.01 and 0.05), there were no significant differences between Group M2 and Group C. The TIMP-1 levels in BALF of atorvastatin groups were significantly lower than those of model groups and control group (P < 0.01 and 0.05), which resulted in a significantly increased ratio of MMP-9 to TIMP-1 in the atorvastatin groups. Atorvastatin inhibits the synthesis and release of MMP-9 and TIMP-1 in the lung tissue of rats with bleomycin-induced pulmonary fibrosis, and has no significant effect on circulating MMP-9 and TIMP-1, which may be associated with the attenuation of experimental pulmonary fibrosis in rats.


Qin Y.,Affiliated Hospital
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology | Year: 2013

To investigate the levels of FasL mRNA in peripheral blood mononualear cells (PBMCs), serum soluble Fas ligand (sFasL) and their regulatory effect on T lymphocyte subsets in patients with severe acute pancreatitis (SAP). Forty-eight patients with pancreatitis were randomly divided into two groups: 20 cases with SAP and 28 cases with mild acute pancreatitis (MAP). Twenty-eight healthy volunteers were selected as control group. The expression of FasL mRNA in PBMCs was detected by real-time quantitative PCR(qRT-PCR), and serum sFasL was measured by ELISA. T lymphocyte subsets in peripheral blood were detected by flow cytometry. Compared with control group and MAP group, FasL mRNA of PBMCs and serum sFasL increased significantly in SAP group (P<0.05), a little increase in MAP group, and there was no significant difference between MAP group and control group (P>0.05). The CD4(+) T cell ratio, CD4(+)/CD8(+) ratio decreased significantly in SAP group (P<0.05) vs control group and MAP group), and they were found negatively related to FasL mRNA, serum sFasL level. The SAP patients showed the significantly increased FasL mRNA of PBMCs and serum sFasL and decreased CD4(+) T-cell ratio, CD4(+)/CD8(+) ratio. FasL may mediate the apoptosis of T lymphocytes.

Loading Affiliated Hospital collaborators
Loading Affiliated Hospital collaborators